Recent Updates
Recently added Catalysts
NKTX Positive Sentiment Score: 65/100

Nkarta to Participate in Upcoming Investor Conference

Tuesday, September 3, 2024 1 min read
Key Takeaway: Nkarta, Inc. (Nasdaq: NKTX) has announced its forthcoming participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company will host a fireside chat at 12:30 p.m. ET, which will also be streamed via webcast for interested investors. Nkarta specializes in developing engineered natural killer (NK) cell therapies, showcasing its commitment to expanding access to innovative biopharmaceutical treatments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a notable investor conference could enhance visibility.
  • Focus on engineered NK cell therapies suggests innovation in treatment.
  • Webcast accessibility allows for widespread investor engagement.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:
H.C. Wainwright 26th Annual Global Investment Conference
12:30 p.m. ET – fireside chat
A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:

Frequently Asked Questions

What is Nkarta, Inc. focused on developing?

Nkarta, Inc. specializes in engineered natural killer (NK) cell therapies.

When is Nkarta participating in the investor conference?

Nkarta will participate in the H.C. Wainwright 26th Annual Global Investment Conference.

Where can I watch the Nkarta conference webcast?

The webcast will be available on Nkarta’s Investors section of their website.

How long will the Nkarta conference replay be available?

The replay of the Nkarta conference will be archived for about 90 days.

What technologies does Nkarta use for cell therapies?

Nkarta combines cell expansion, cryopreservation, and CRISPR-based engineering.

Tags: NKTX Viatris Investor Conferences Healthcare Nkarta H.C. Wainwright NK cell therapies biopharmaceutical Nasdaq
Last updated: Sep 3, 2024